Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NRG-GY002||NRG||A Phase II Evaluation of Nivolumab; a Fully Human Antibody against PD-1; in the Treatment of Persistent or Recurrent Cervical Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|NRG-GU009||NRG||Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU007||NRG||Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-BR005||NRG||A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-LU003||NRG||A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY012||NRG||A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN005||NRG||A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GI001||NRG||Randomized Phase III Study of Focal Radiation Therapy for Unresectable; Localized Intrahepatic Cholangiocarcinoma||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-43||NSABP||A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|